Brief: Hepion Pharmaceuticals Announces Positive Topline Data From Phase 2A ‘AMBITION’ Nash Trial
13/07/2021 13:27
July 13 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O :
* HEPION PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE DATA
FROM
PHASE 2A ‘AMBITION’ NASH TRIAL; ALL PRIMARY ENDPOINTS ACHIEVED
* HEPION PHARMACEUTICALS INC - CONCENTRATION-EFFECT
RELATIONSHIP
DEMONSTRATED FOR ALT REDUCTIONS
* HEPION PHARMACEUTICALS INC - MULTIOMIC ANALYSES AND
MACHINE
LEARNING PAVING WAY FOR PHASE 2B, ANTICIPATED TO START LATER IN
2021
* HEPION PHARMACEUTICALS INC - CRV431 AT BOTH STUDY DOSES
WAS WELL
TOLERATED, AND THERE WERE NO SERIOUS ADVERSE EVENTS
Source text for Eikon: ID:nGNX12ffzM
Further company coverage: HEPA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement